These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17641012)

  • 1. Xenogeneic beta 2-microglobulin substitution alters NK cell function.
    Benoît LA; Tan R
    J Immunol; 2007 Aug; 179(3):1466-74. PubMed ID: 17641012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of xenogeneic beta2-microglobulin on functional recognition of H-2Kb by the NK cell inhibitory receptor Ly49C.
    Benoit LA; Shannon J; Chamberlain JW; Miller RG
    J Immunol; 2005 Sep; 175(6):3542-53. PubMed ID: 16148097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD1d-independent NKT cells in beta 2-microglobulin-deficient mice have hybrid phenotype and function of NK and T cells.
    Maeda M; Shadeo A; MacFadyen AM; Takei F
    J Immunol; 2004 May; 172(10):6115-22. PubMed ID: 15128797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
    Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
    Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ly49-dependent NK cell licensing and effector inhibition involve the same interaction site on MHC ligands.
    Choi T; Ferris ST; Matsumoto N; Poursine-Laurent J; Yokoyama WM
    J Immunol; 2011 Apr; 186(7):3911-7. PubMed ID: 21335486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC class Ia molecules alone control NK-mediated bone marrow graft rejection.
    Grigoriadou K; Ménard C; Pérarnau B; Lemonnier FA
    Eur J Immunol; 1999 Nov; 29(11):3683-90. PubMed ID: 10556824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta2-microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains.
    Höglund P; Glas R; Ménard C; Kåse A; Johansson MH; Franksson L; Lemmonier F; Kärre K
    Eur J Immunol; 1998 Jan; 28(1):370-8. PubMed ID: 9485216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major histocompatibility complex genes determine natural killer cell tolerance.
    Dorfman JR; Raulet DH
    Eur J Immunol; 1996 Jan; 26(1):151-5. PubMed ID: 8566058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1.
    Lowin-Kropf B; Kunz B; Beermann F; Held W
    J Immunol; 2000 Aug; 165(3):1314-21. PubMed ID: 10903732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class I mosaic mice reveal insights into control of Ly49C inhibitory receptor expression in NK cells.
    Andersson M; Freland S; Johansson MH; Wallin R; Sandberg JK; Chambers BJ; Christensson B; Lendahl U; Lemieux S; Salcedo M; Ljunggren HG
    J Immunol; 1998 Dec; 161(12):6475-9. PubMed ID: 9862670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance and alloreactivity of the Ly49D subset of murine NK cells.
    George TC; Ortaldo JR; Lemieux S; Kumar V; Bennett M
    J Immunol; 1999 Aug; 163(4):1859-67. PubMed ID: 10438920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro.
    Kambayashi T; Michaëlsson J; Fahlén L; Chambers BJ; Sentman CL; Kärre K; Ljunggren HG
    Eur J Immunol; 2001 Mar; 31(3):869-75. PubMed ID: 11241292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the NK cell alloreactivity to bone marrow cells by the combination of the host NK gene complex and MHC haplotypes.
    Iizuka K; Scalzo AA; Xian H; Yokoyama WM
    J Immunol; 2008 Mar; 180(5):3260-7. PubMed ID: 18292550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cell tolerance in mixed allogeneic chimeras.
    Zhao Y; Ohdan H; Manilay JO; Sykes M
    J Immunol; 2003 Jun; 170(11):5398-405. PubMed ID: 12759414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
    Karlhofer FM; Ribaudo RK; Yokoyama WM
    Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine tuning of natural killer cell specificity and maintenance of self tolerance in MHC class I-deficient mice.
    Salcedo M; Andersson M; Lemieux S; Van Kaer L; Chambers BJ; Ljunggren HG
    Eur J Immunol; 1998 Apr; 28(4):1315-21. PubMed ID: 9565371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis.
    Chiang EY; Henson M; Stroynowski I
    J Immunol; 2002 Mar; 168(5):2200-11. PubMed ID: 11859106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of the Major Histocompatibility Complex (MHC) Class Ib Molecule H2-Q10 by the Natural Killer Cell Receptor Ly49C.
    Sullivan LC; Berry R; Sosnin N; Widjaja JM; Deuss FA; Balaji GR; LaGruta NL; Mirams M; Trapani JA; Rossjohn J; Brooks AG; Andrews DM
    J Biol Chem; 2016 Sep; 291(36):18740-52. PubMed ID: 27385590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates.
    Surquin M; Le Moine A; Flamand V; Nagy N; Rombaut K; Demoor FX; Stordeur P; Salmon I; Guéry JC; Goldman M; Abramowicz D
    J Immunol; 2002 Jul; 169(1):500-6. PubMed ID: 12077281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ly49I NK cell receptor transgene inhibition of rejection of H2b mouse bone marrow transplants.
    Liu J; Morris MA; Nguyen P; George TC; Koulich E; Lai WC; Schatzle JD; Kumar V; Bennett M
    J Immunol; 2000 Feb; 164(4):1793-9. PubMed ID: 10657626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.